The beverage giant Dongpeng Beverage with a market cap of 100 billion is going for an IPO again. Last year, the company's performance grew by more than 60% year-on-year | Read the announcement.

① Dongpeng Beverage plans to issue H Shares and list on the Main Board of the Hong Kong Stock Exchange. ② The revenue proportion of Dongpeng Beverage's "home base" in the Guangdong region for 2024 has decreased compared to the previous year, but it is still the region with the highest revenue share. ③ Dongpeng Beverage hopes to further expand into overseas markets through its listing in Hong Kong, with Southeast Asia being a key focus market.

cls.cnMar 7 21:28 ET

Analysis of the Cabio Biotech(Wuhan) acquisition case: How does the symbol Ouyi Bio support a valuation of 1.3 billion with earnings of 0.043 billion over three quarters?|Focus

① Jinzheng Assessment stated that future expected profitability is at the core of a company's value, and it is estimated that Ouyi Biological's revenue will reach 0.48 billion yuan, 0.558 billion yuan, and 0.637 billion yuan from 2025 to 2027 respectively; ② "Valuation inclusivity does not mean accepting overvaluations, but rather accepting valuations that clearly analyze the business logic and valuation logic of mergers and acquisitions," said Lin Li, president of Jinzheng Assessment.

cls.cnMar 6 21:36 ET

The trade price is 0.831 billion yuan! Cabio Biotech(Wuhan) disclosed the latest restructuring plan: it intends to reduce one trading counterpart and raise 0.269 billion yuan through a private placement.

① Both parties signed a performance commitment, promising that the Net income of Ouyi Biotech will not be less than 0.27 billion yuan in total for the fiscal years 2025, 2026, and 2027; ② The profits of Cabio Biotech(Wuhan) are expected to further increase. The company estimates that its revenue for the first three quarters of 2024 will rise from 0.387 billion yuan before the Trade to 0.655 billion yuan; the Net income attributable to the parent company will increase from 83.8902 million yuan to 0.113 billion yuan.

cls.cnMar 4 19:47 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Hunan enterprises are speeding up their overseas expansion! Yanker Shop Food and Huaci Co., Ltd. announced the construction of a factory in Southeast Asia on the same day | Quick read of the announcement.

① "Going global" has gradually become a consensus among many listed companies in Hunan. This evening, Huaci Co., Ltd. and Yanker Shop Food both issued announcements stating that they will lay out production bases in Southeast Asia to promote the expansion of overseas business; ② The listed companies mentioned that Vietnam has relatively low labor costs and local production resources, which can effectively reduce company production costs; through supply chain layout, the company can also enhance its market competitiveness and brand recognition.

cls.cnFeb 24 09:37 ET

Retail channels are under pressure, and Yihai Kerry Arawana Holdings' performance last year declined by more than 10% year-on-year, planning to further extend the Industry Chain | Interpretations.

① The main products saw an increase in volume but a decrease in price, with Yihai Kerry Arawana Holdings' revenue and Net income both declining year-on-year in 2024; ② The company established a subsidiary with Jiangxi Fushine Pharmaceutical, with company personnel stating that this move aims to extend the Industry Chain and enrich downstream products.

cls.cnFeb 20 08:28 ET